Navigation Links
Sixth U.S. Patent Issued to Dyadic International
Date:10/13/2010

JUPITER, Fla., Oct. 13 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,794,962 by the United States Patent and Trademark Office ("USPTO").

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO)

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

The invention embodied by this patent provides a method for the expression and subsequent screening of DNA libraries in filamentous fungal hosts which may help speed up the discovery of novel genes and development of their corresponding enzymes and proteins. The newly issued patent is accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

This patent is the sixth U.S. patent issued to Dyadic adding to its portfolio of 60 international patents and more than 40 pending patent applications worldwide which cover various features of Dyadic's proprietary technologies.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "As with our entire patent portfolio, we believe that this patent will help us further enhance our intellectual property protection of Dyadic's cutting edge technologies, provide additional potential licensing opportunities and strengthen our competitive market position."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
2. Connectyx Announces MedFlash(R) Sixth Man Fan Promotion in Conjunction With Walgreens and The Orlando Magic
3. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
4. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
5. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
8. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
11. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/26/2017)... St. Louis, Missouri (PRWEB) , ... April 26, ... ... optimal cost, quality and clinical outcomes, today released the podcast, “Make Plans ... Act in bringing value-based payment into the physician's office and how physicians and ...
(Date:4/26/2017)... N.J. (PRWEB) , ... April 26, 2017 , ... ... Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine as ... that recognizes the world’s top women business owners. Winners have demonstrated that they ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
Breaking Medicine News(10 mins):